Patients treated with imatinib, dasatinib, and nilotinib have shown meaningful rates of hematologic and cytogenetic response.
Accelerated phase chronic myelogenous leukemia
Chronic phase chronic myelogenous leukemia
Blastic phase chronic myelogenous leukemia
AIDS-related lymphoma
Atypical chronic myeloid leukemia
Prefibrotic primary myelofibrosis
Mixed-phenotype acute leukemia
Refractory cytopenia of childhood